PHILADELPHIA ‚ÄĒ Most ovarian cancer patients are diagnosed with late stage disease that is unresponsive to existing therapies. In a new study, researchers from the Perelman School of Medicine at the University of Pennsylvania School of Medicine show that a two-step personalized immunotherapy treatment ‚ÄĒ a dendritic cell vaccine using patients‚Äô own tumor followed by adoptive T cell therapy ‚ÄĒ triggers anti-tumor immune responses in these type of patients. Four of the six patients treated in the trial responded to the therapy, the investigators report this month in OncoImmunology.
"What we proved in this study is that this is a safe treatment strategy," says co-first author Lana Kandalaft, PharmD, MTR, PhD, research assistant professor of Obstetrics and Gynecology and director of clinical development in the Ovarian Cancer Research Center. "It is a walk in the park for patients, especially compared to standard chemotherapies and surgical treatments for ovarian cancer ‚Äď literally, some patients left the clinic and went for a walk in a nearby park after their treatment."
The findings follow research by the study‚Äôs senior author, George Coukos, MD, PhD, director of the Ovarian Cancer Research Center at Penn, who showed in 2003 that women whose ovarian tumors were infiltrated by healthy immune cells, called T cells, tended to live longer than women whose tumors were devoid of T cells. That observation and other subsequent ones suggest the patient's immune system is trying to fight off the disease but can't quite muster the strength to beat it. Therefore, investigators have been trying to find ways using patients‚Äô own tumor cells to boost the immune system's power.
In the current study, Coukos, Kandalaft, co-first author Daniel J. Powell Jr., PhD, research assistant professor of Pathology and Laboratory Medicine, and colleagues treated six women with advanced ovarian cancer in a two-staged immunotherapy protocol in which they utilized a dendritic cell vaccine created from tissue in the patients‚Äô own tumor, which was stored at time of surgery. All of these women‚Äôs cancers had progressed on standard of care chemotherapy.
In the first segment of the study, the team prepared an individualized dendritic cell vaccine for each patient. They harvested dendritic cells from each patient using apheresis, the same process volunteers go through when they donate platelets or other blood products such as those collected for stem cell transplants. Kandalaft and colleagues then exposed each patient's dendritic cells to tumor extract produced from the woman's own tumor, which teaches the dendritic cells who the enemy is. After this priming, the investigators vaccinated each patient with her own dendritic cells and gave them a combination chemotherapy regimen of bevacizumab and cyclophosphamide. Because dendritic cells are like the generals of the immune system, they then induce other immune cells to take up the fight.
Click here to view the full release.